The unexpected discovery of a second form of the estrogen receptor (ER), designated ER␤, surprised and energized the field of estrogen research. In the 9 yr since its identification, the remarkable efforts from academic and industrial scientists of many disciplines have made significant progress in elucidating its biology. A powerful battery of tools, including knockout mice as well as a panel of receptor-selective agonists, has allowed an investigation into the role of ER␤. To date, in vivo efficacy studies are limited to rodents. Current data indicate that ER␤ plays a minor role in mediating estrogen action in the uterus, on the hypothalamus/ pituitary, the skeleton, and other classic estrogen target tissues. However, a clear role for ER␤ has been established in the ovary, cardiovascular system, and brain as well as in several animal models of inflammation including arthritis, endometriosis, inflammatory bowel disease, and sepsis. The next phase of research will focus on elucidating, at a molecular level, how ER␤ exerts these diverse effects and exploring the clinical utility of ER␤-selective agonists. (Molecular Endocrinology 21: 1-13, 2007) E STROGENS, LIKE MANY other hormones, elicit a myriad of biological responses, and it has been appreciated since the early 1960s that these actions are receptor mediated. When an estrogen receptor (ER) was cloned in 1986 (1, 2) and its ablation in mice had the expected phenotype in many organ systems (3), it seemed a plausible conclusion that only one ER existed. However in 1996, Jan-Ake Gustafsson announced at a Keystone Symposium that his group had discovered a second form of the ER, necessitating the first cloned receptor be renamed ER␣. This second receptor, designated ER␤ (4), was unexpectedly found while searching for additional androgen receptors using a rat prostate cDNA library and degenerate PCR primers. It would not be an overstatement to say that this discovery electrified the field of estrogen biology, causing a reexamination of all our understandings and assumptions about the mechanism of estrogen action.
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Early studies, naturally, focused on cloning ER␤ from additional species (5, 6) and describing ER␤'s ligand specificity (7) (8) (9) and tissue distribution (10) (11) (12) (13) . Two key conclusions can be drawn from this body of work: First, 17␤-estradiol is the most potent endogenous ligand for ER␤, and it binds equally well to ER␣ and ER␤. Second, ER␤ is widely distributed, although it is not highly expressed in the uterus. One logical extrapolation of this information is that a selective ER␤ ligand would be expected to mimic estradiol's actions in a variety of target tissues but would have less impact on the uterus. This was the premise behind part of the drive to identify/design selective ligands: not only could these compounds help dissect ER␣ from ER␤ function but they might also carry clinical benefits. Early speculation about potential clinical benefits was primarily related to the treatment of menopausal disorders such as osteoporosis, cardiovascular disease, cognition, and urinary incontinence (14) . If this list seems expansive and unduly ambitious, recall that ER␤'s discovery came at a time when estrogen therapy in postmenopausal women was thought (at least at a research level) to potentially confer benefits on almost all organ systems and was prescribed clinically for long-term use.
This article will review the current state of knowledge about the function of ER␤ and will be biased toward discussion of recent in vivo data generated from ER␣ and ER␤ knockout (KO) mice as well as a summary of the preclinical characterization of ER␣-and ER␤-selective agonists. A number of other reviews on ER␤ have recently been published that examine estrogen action in general and lessons learned from in vitro studies (15) (16) (17) .
SUMMARY OF AVAILABLE TOOLS AND CAVEATS

ERKO Mice
Mice lacking both ER subtypes have been produced. Two versions of ␣ERKO mice exist. The first mouse constructed (Ref. 3 ; designated ␣ERKO CH in this review) is still the most widely used, but residual effects of estrogens in this animal cannot be automatically attributed to ER␤ because of low levels of ER␣ splice variants that retain some activity (18) . More recently, an apparently complete KO of ER␣ has been accomplished, and these mice will be designated ␣ERKO ST (19) .
Three groups have independently constructed mice lacking ER␤, and there is disagreement in the field as to their phenotype. In this article, ␤ERKO mice will be designated as follows: ␤ERKO CH for the mice produced in Chapel Hill by Krege et al. (20) that are commercially available from Taconic Farms, Inc. (Germantown, NY); ␤ERKO KI for the colony of these mice that were subsequently established at the Karolinska Institute; ␤ERKO ST for the mice produced by Dupont et al. (19) in Strasbourg, France; and ␤ERKO WYE for the mice produced by Wyeth (21) .
Although independently generated KO mice might not be expected to exhibit identical phenotypes, the issue confronting scientists studying ␤ERKO mice is unexpected in that investigators studying ␤ERKO CH and ␤ERKO KI observe markedly different phenotypes (detailed examples discussed below), whereas the ␤ERKO ST and ␤ERKO WYE mice seem similar to the ␤ERKO CH mice. Potential explanations for the phenotype differences have been discussed but not rigorously tested. One hypothesis is that factors present in the ␤ERKO KI environment elicit the phenotypes seen. These might include dietary differences or the presence of endemic pathogens. This hypothesis is readily testable by cohousing ␤ERKO CH mice with ␤ERKO KI mice in the Karolinska Institute's colony, but this has not been done as yet. Although the data generated from the ␤ERKO KI mice are dramatic and provide compelling evidence for a role for ER␤ in a variety of diseases, it is very puzzling that similar observations have not been made in other ␤ERKO mice. As with the selective compound data discussed below, and indeed with any scientific observation, the dataset inspiring the highest confidence is obtained from independently corroborating observations.
Selective Small Molecules
A number of selective ER␤ agonists have been described in the peer-reviewed scientific literature (see Ref.
22 for a comprehensive review including patent sources), but a minority has been evaluated extensively in vivo. These include DPN (23), ERB-041 (24) , WAY-202196 (25) , WAY-200070 (24) , and 8␤-VE 2 (26) (Fig. 1) . Selectivity of these compounds was measured in in vitro screens using transcriptional assays and/or competitive radioligand-binding assays. All of these compounds are at least 70-fold selective for ER␤ over ER␣ (based on a radioligand-binding assay), and their potencies range from 18-180% that of 17␤-estradiol (Table 1) .
Two highly selective ER␣ agonists have been described and characterized in vivo. These are PPT (27, 28) and 16␣-LE 2 (26, 29) , and their structures are shown in Fig. 1 . In some publications, 16␣-LE 2 is known as Cpd1471 (30). In competitive radioligandbinding assays, these compounds are at least 250-fold selective for ER␣ and have potencies of about 50-60% that of 17␤-estradiol (Table 1) . Taken together with the ER␤-selective agonists, these reagents are powerful tools to elucidate the respective functions of ER␣ and ER␤.
Although good comparative data exist for both types of ER-selective compounds on classic estrogenic endpoints and the results are, by-and-large, consistent (see below), relatively few studies have been published on the ER␤ agonists' positive in vivo activity, and few direct comparisons have been made.
Fig. 1. Structures of Selective ER Agonists
Therefore, it is premature to make many statements about ER␤ class effects that will be shared among all members. Just as selective ER modulators can vary in their efficacy on a given target, it is to be expected that even bona fide selective ER␤ agonists will exhibit a range of activities. Moreover, typically these ER␤-selective compounds were classified as agonists based on their profile in (an often) contrived in vitro model or using three-dimensional x-ray cocrystal structure. It is entirely possible that the compounds described to date do not elicit the full range of biological activities able to be exhibited by ER␤. Thus, the accurate definition of ER␤-mediated activities requires the simultaneous testing of a wide range of highly selective ligands in a variety of in vivo models.
ER␣ MEDIATES THE MAJORITY OF ESTROGENS EFFECTS ON CLASSIC ESTROGEN TARGET TISSUES
Estrogens that lack marked selectivity for either ER, such as 17␤-estradiol or 17␣-ethinyl-17␤-estradiol, have well-characterized and familiar effects on several organ systems. These include stimulation of the uterus, facilitation of proliferation/endbud development in the mammary gland, control of ovulation, maintenance of bone mineral density, and negative feedback to the hypothalamus and pituitary. As has been reviewed extensively elsewhere (16, 31), mice not expressing ER␣ lack many of these responses. Although the published literature is not unanimous on the subject, on balance, the data suggest that ER␤ plays a minor role in several organs/organ systems that are highly responsive to estrogens. These are discussed in more detail below. (32) . In contrast to these findings, the ␤ERKO KI mice exhibit an enhanced response to estrogenic stimulation as measured by luminal fluid production and expression of complement C3 protein (33).
Uterus
The data gathered from selective ER agonists are consistent with the KO mouse phenotype, suggesting a minor role for ER␤ in uterine physiology. ER␣ appears to be necessary and sufficient to mediate estrogen's increase in wet weight (at least in rats) as evidenced by the fact that PPT (28) and 16␣-LE 2 (26) are as efficacious as reference estrogens on this endpoint. In terms of ER␤-selective compound activity, uterine weight has been measured for all five selective agonists. DPN, ERB-041, WAY-202196, and WAY-200070 do not significantly increase uterine weight at Ն50 mg/kg when given sc to rats and/or mice (Refs. 24 and 25; and Harris, H. A., unpublished observations). The steroidal selective agonist, 8␤-VE 2 , increased uterine weight at a sc dose of 0.5 mg/kg. It is interesting to note that the in vivo selectivity of 8␤-VE 2 is more in line with expectations based on its in vitro selectivity than the other compounds, which appear more selective in vivo that what would be predicted from their in vitro potency and selectivity. There are potential explanations for this observation. First, there is not an exact relationship between binding and activity. Second, these compounds are likely differentially bound to plasma proteins and/or metabolized.
Mammary Gland
Data from ␣ERKO CH , ␤ERKO CH , and transgenic aromatase/␣ERKO CH mice clearly indicate that ER␤ is not required for normal mouse mammary gland development or function (16, 34) . In contrast, ␤ERKO KI mice have enlarged alveoli and reduced expression of several markers of differentiation and a concomitant increase in the proliferation marker Ki67 (35). Little published data currently exist on the effects of selective ER agonists on estrogen-dependent functions in the mammary gland.
Hypothalamic/Pituitary Effects
In contrast to ␣ERKO CH mice, ␤ERKO CH mice have normal circulating levels of LH and estradiol (36), suggesting that ER␣ controls the negative feedback of estrogens to the brain (16) . Similar to estradiol, 16␣-LE 2 suppressed LH and FSH production in the ovariectomized rat, again showing ER␣ sufficiency in mediating this negative feedback loop. When administered at nonuterotrophic doses, the ER␤-selective agonists DPN, WAY-200070, and 8␤-VE 2 had no effect on FSH and/or LH nor did they inhibit ovulation, suggesting the inability of ER␤ to influence this axis (26, 29, 37, 38) . Another well-known effect of estrogens on the pituitary is the stimulation of prolactin secretion. In mice, PPT increased prolactin levels whereas DPN had no effect. It should be noted that the efficacy of PPT was less than that of estradiol at the dose tested, but that a full dose-response study was not performed (39).
Skeleton
Careful characterization of ER null mice has shown a variety of phenotypes, suggesting that both ER␣ and ER␤ play a role in bone development. However, these effects are not seen at all ages in both genders or all investigators' ␤ERKO mice (see Ref. 36 for review). Moreover, estradiol protected against ovariectomyinduced bone loss in ␤ERKO mice, indicating that ER␤ is not necessary for this activity. Extrapolation of these findings in rodents to effects in humans is problematic; however, an unambiguous role was established for the necessity of ER␣ in normal bone development when a human male was discovered with an inactivating mutation in this receptor (40). This individual had unfused epiphyses and markedly reduced bone mineral density and was unresponsive to estradiol therapy.
The activity of selective ER␤ agonists supports the idea that ER␤ is not a major player in estradiol's maintenance of adult skeletal mass. As with the uterine responses, selective ER␣ stimulation with PPT or 16␣-LE 2 is as efficacious as a reference estrogen at preservation of bone mineral density after ovariectomy in rats (26, 28) , whereas ERB-041, WAY-200070 or 8␤-VE 2 were inactive at nonuterotrophic doses (24, 26, 41) .
Ovarian Physiology
ER␤ is highly expressed in the granulosa cell, and all types of ␤ERKO mice are subfertile. Ovaries from both ␤ERKO CH and ␤ERKO ST mice have fewer corpa lutea than their wild-type counterparts but only the ␤ERKO CH mice showed an increase in the number of atretic follicles (19, 20) . Under gonadotropin stimulation, ␤ERKO CH and ␤ERKO ST mice produced fewer oocytes, although the severity of impairment varied and likely represented partial compensation in some animals by ER␣. These data indicate a role for ER␤ in folliculogenesis and are supported by the activity of 8␤-VE 2 in the hypophysectomized rat (29).
Potential for ER␤-Selective Compounds to Block Estradiol's Activity
Given the inactivity of selective ER␤ agonists in classic estrogen target tissues, several studies have examined the potential for these compounds to block a reference estrogen's effects. In the uterus, when WAY-200070, ERB-041, or 8␤-VE 2 are coadministered with 17␤-estradiol, these compounds do not block the estradiol-mediated increase in uterine weight (24, 26, 41) . Additionally, WAY-200070 did not block the antiresorptive effects of 17␤-estradiol in rat models of osteopenia (24) , and 8␤-VE 2 was unable to block 17␤-estradiol's effects on pituitary (gonadotropins) or liver (angiotensin I, IGF-I, high density lipoprotein, or total cholesterol) responses (26) . DPN did not antagonize PPT effects on LH, FSH, or prolactin (37).
Frasor et al. (39) have found that DPN has the potential to mildly antagonize the uterine effects of PPT. In the mouse, coadministration of DPN with a modest dose of PPT led to a 30% reduction of PPT-induced wet weight. Additionally, mild inhibitory effects were seen on some mRNA markers of estrogen action in the uterus. On the other hand, DPN had modest stimulatory effects on the activity of PPT on other markers of estrogen action. It remains to be determined whether these effects indicate a subtle modulatory effect of ER␤ on uterine response to estrogens or if they are observations specific to DPN.
ROLES FOR ER␤ IN NONREPRODUCTIVE ORGAN SYSTEMS
ER␤'s activity has been investigated in a number of in vivo models, some using KO mice and others using selective agonists. Major areas of investigation are presented below, grouped roughly by organ system or disease type.
Prostatic Actions
The role of estrogens in prostatic physiology is controversial. Historically, high doses of estrogens were used to treat prostate cancer, but it was thought to act via down-regulation of gonadotropins. When ER␤ was discovered in the prostate epithelium, it stimulated investigation of direct interactions of estrogens on the prostate. Although neonatal exposure to high amounts of estrogens alters prostate development, two studies using KO mice (␤ERKO KI , ␤ERKO CH , and ␣ERKO CH ) clearly show this imprinting is mediated by ER␣ (42, 43) .
Older ␤ERKO KI mice have hyperplastic prostates (44), a phenotype that is not seen in ␤ERKO CH (42, 45) or ␤ERKO ST (19) mice. In addition to abnormal histological changes in these mice, markers of proliferation are increased and androgen receptor (protein) expression is increased. It appears that the prostate locally produces a dihydrotestosterone metabolite that is ligand for both ERs: 5␣-androstane-3␤,17␤-diol (44) . Exogenous administration of this compound to mice decreased markers of cell proliferation in the developing prostate of wild-type mice and this effect was absent in ␤ERKO KI mice (46) . However, as pointed out by Taylor et al. (47) , because the prostate is so androgen sensitive, it is difficult to separate direct effects of estrogens on this organ from their ability to modulate androgen action. Accordingly, this group used organ cultures of prostates isolated from rats (newborn) or wild-type ␣ERKO CH , and ␤ERKO CH mice (postnatal d 1). In cultures of both rat and mouse prostates, testosterone supports growth and branching, whereas coadministration of estradiol reduced growth and promoted apoptosis, especially in the distal epithelial cells (areas of active branching). These proapoptotic effects were seen in both ␣ERKO CH and ␤ERKO CH mice, suggesting neither ER is involved. Because double KO mice were not available, selective agonists were used to try and mimic estradiol's effects. However, neither PPT, DPN, nor 5␣-androstane-3␤,17␤-diol could replicate the effects of estradiol on the explants, although they each had other effects on prostate morphology. It should be noted that although low levels of testosterone were required to maintain tissue development, very high concentrations of estradiol were used to see the proapoptotic effects (15 M). These concentrations are similar to those used for neonatal imprinting studies but may have little relevance to adult exposures. Further analysis of the estradiol-treated prostates showed that ER␤ protein was up-regulated, and androgen receptor protein was down-regulated in distal areas of prostates, regardless of genotype. Thus estrogens, especially at pharmacological doses in the developing organ, may impact prostate physiology independent of either ER.
Vasomotor Instability
Estrogens are frequently prescribed for the relief of hot flushes in peri-or postmenopausal women. Both ERs are expressed in the hypothalamus, the thermoregulatory center of the brain; therefore it is possible that estrogen's suppression of vasomotor instability could be mediated by ER␤ and/or ER␣. This question has been investigated using both KO mice and selective ER agonists, and studies agree that activation of ER␣ is sufficient to modulate tail skin temperature in the rodent, an animal model of hot flush. First, PPT was as effective as ethinyl estradiol at reducing tail skin temperature changes induced by acute morphine withdrawal in ovariectomized rats (28). Second, Opas et al. (48) found that estradiol cypionate was as effective at suppressing ovariectomy-induced tail skin temperature increase in ␤ERKO CH as wild-type mice. The data on whether ER␤ activation has a similar effect are mixed. In the Opas et al. study mentioned above, estradiol cypionate also worked well in ovariectomized ␣ERKO CH mice, whereas WAY-200070 was inactive in the morphine model (24) . Additional studies are needed to resolve this apparent inconsistency as to the role of ER␤ in mediating estrogen's actions on hot flushes.
Cardiovascular System
Estrogens have well-appreciated effects on the cardiovascular system in preclinical models, but human clinical trial data have not been unanimously supportive. Reasons behind this apparent discrepancy are under investigation (see Ref. 49 for review) and may depend on the age at which treatment is given (50) . Despite this controversy, enthusiasm for defining the role of the ER subtypes in mediating estrogen's preclinical effects remains high. KO mice and selective ER agonists have been used to investigate the relative contributions of ER␤ and ER␣ in models of vascular injury, vascular function, and cardiac injury.
After carotid artery denudation, vascular smooth muscle cells proliferate, leading to a narrowing of the vessel lumen. Estradiol can prevent this neointima formation in both rats and mice. Early studies using ␣ERKO CH mice suggested estradiol might work via ER␣ or ER␤ to prevent intimal thickening, but more recent data from ␣ERKO ST mice suggest ER␣ is the sole receptor responsible (51) . No highly subtype-selective agonists have been tested in this model; thus it remains to be seen whether these tools will confirm observations from the KO mice.
Several studies have examined ER subtype effects on vascular function. Estradiol does not reduce phenylephrine-induced contraction in endothelial-denuded aortic vascular rings of ␤ERKO CH mice as it does in wild-type mice, and this defect is due to reduced inducible nitric oxide synthase produced (52) . In keeping with these results, rat aortic rings with intact endothelia precontracted with noradrenaline relaxed significantly when treated acutely with nanomolar levels of estradiol or PPT, whereas DPN had no significant effect over a concentration range expected to be selective for ER␤ (53) . The PPT effect was blocked by ICI-182780, strongly suggesting an ER-dependent effect. These data suggest ER␣ mediates relaxation effects but is in contrast to the work reported by others (54, 55) that use PPT and DPN to support a role for both ERs. However, these other studies used very high (Ͼ1 M) concentrations of compounds that are clearly pharmacological and beyond the range where these compounds are ER␣ or ER␤ selective in in vitro assays (23, 27) . A study in the spontaneously hypertensive rat confirms an obligatory role for ER␣ in mediating vessel relaxation (56) . In this study, ovariectomized rats were treated for 4 wk, after which aortic rings were isolated for testing. Aortic tissue from rats treated with estradiol or 16␣-LE 2 (Cpd1471) and precontracted with KCl was more responsive to acetylcholine-induced relaxation than tissue from ovariectomized rats. These effects were mediated by the endothelium, as contraction/relaxation profiles of denuded aortic rings were not different between the treatment groups. Moreover, endothelial nitric oxide synthase was up-regulated by treatment with estradiol and 16␣-LE 2 , again pointing to an ER␣-dependent effect on the endothelium.
Three studies have looked at in vivo effects of ER subtypes in models of cardiac injury. Korte et al. (57) looked at the effect of ER␣ or ER␤ deletion on various cardiac functions after anterior myocardial infarction. Genotype did not influence mortality or infarction size [in contrast to the findings of Pelzer (58) discussed below]. Moreover, the ␣ERKO ST mice had no defects in ECG parameters. In contrast, the ␤ERKO CH mice had prolonged QT, QTc, JT, and JTc after infarction when compared with wild-type mice (regardless of injury) and sham-operated ␤ERKO CH controls. Moreover, there was a dramatic ER␤-dependent reduction in ventricular premature beats. These phenomena may be attributed to decreased expression of the potassium channel Kv4.3 mRNA seen in the ␤ERKO CH mice.
In a similar study of chronic anterior myocardial infarction, ␤ERKO CH mice had lower survival rates, retained more fluid, and had elevated levels of ventricular pro-atrial naturetic peptide than their wild-type counterparts. Thus, although the data are not entirely concordant, both studies conclude that ER␤ plays a role in the response to myocardial infarction. Future studies will likely test whether selective ER agonists are protective in this model.
Finally, in an ex vivo ischemia/reperfusion model using hearts excised from ␣ERKO CH and ␤ERKO CH mice and treated with isoproterenol, Gabel et al. (59) found that female hearts sustained less injury (as measured by a reduction in infarction size) than males, and that this was attributable to ER␤. Expression profiling suggested that ␤ERKO CH females had reduced levels of various genes involved in fatty acid metabolism, thus perhaps providing a mechanistic explanation.
When the heart is subjected to increased pressure via aortic constriction, cardiac hypertrophy develops. Skavdahl et al. (60) observed that male mice developed larger hearts than females and further discovered, using ␣ERKO CH and ␤ERKO CH mice, that ER␤ was responsible for this attenuation. However, a study in spontaneously hypertensive rats indicates that stimulation of ER␣ is protective (30). These rats develop cardiac hypertrophy as a consequence of chronically elevated blood pressure. Although estradiol or 16␣-LE 2 treatment for 12 wk did not lower blood pressure, both compounds reduced heart weight and improved cardiac function. These effects were blocked by ICI-182780, indicating the activity depends on an ER. It remains to be seen whether ER␤ agonists can also achieve this effect. It will also be interesting to determine the effect of selective ER␤ agonists on blood pressure because the ␤ERKO CH mice have hypertension (52).
Brain and Behavior
ER␤ is expressed throughout the brain (see Ref. 10 for review), and there has been much interest in defining its function. Specific areas of investigation have been stroke/neuroprotection, anxiety/depression, and learning/memory.
Estrogens protect against neuronal cell loss in a variety of ischemic stroke models. These models differ in whether the tissue is reperfused and the level of estradiol required for protection; thus the data are not entirely comparable. Early data using ␤ERKO WYE and ␣ERKO CH mice indicated an obligatory role for ER␣ (61) in preserving neurons after middle cerebral artery occlusion leading to permanent cerebral ischemia. More recently, using a 15-min global ischemic insult, followed by reperfusion, DPN significantly reduced neuronal damage in the caudate nucleus and CA1 pyramidal cell layer (62) One area of particularly active investigation is whether ER␤ might ameliorate anxiety and/or depression. Support for this hypothesis is derived from distribution studies as well as estradiol/ER␤ influences on the serotonergic system. Double immunolabeling studies show that more than 90% of ER␤-expressing neurons also express tryptophan hydroxylase, the rate-limiting step in serotonin synthesis; although deletion of ER␤ in ␤ERKO CH mice does not affect its expression (63) . A functional connection between these two proteins was made by the discovery that estradiol up-regulates tryptophan hydroxylase-1 mRNA via ER␤ in the dorsal raphe nucleus and shown by comparing estradiol's activity in wild-type and ␤ERKO CH mice (64) . Interestingly, such regulation may have a local effect in the midbrain, because estradiol does not affect tryptophan hydroxylase-2, the more widely expressed isoform. It remains to be shown whether this increase in mRNA translates to increased protein expression.
A number of behavioral studies have been published that use either KO mice or selective ER agonists to investigate the effects of ER␤ on anxiety and/or depression. In the forced swim test model of depression using mice, estradiol reduced immobility time comparably to a reference compound, desiprimine, and estradiol's effect (but not that of desiprimine) was lost in ␤ERKO CH mice (65) . ␣ERKO mice have not been evaluated as yet. Rats' performance in the forced swim test also implicates a role for ER␤: immobility times were similarly reduced when rats were given estradiol, DPN, and desiprimine, but PPT had no effect (66) .
In a model measuring anxiety, Krezel et al. (67) reported an increase in anxiety-related behaviors of ␤ERKO ST female mice in the elevated plus maze or in the open-field test, perhaps attributable to abnormalities in the amygdala. These behavioral observations were confirmed by Inwalle et al. (68) using ␤ERKO CH mice, and it was further reported that estradiol did not influence the behavior of either genotype. Two other studies used rats and measured the time they spent in a lighted open field or the open arm of an elevated plus maze (69, 70) . Estradiol and DPN clearly increased time spent in the open area, and PPT had no effect although it affected other behaviors. Moreover, these antianxiety effects of estradiol and DPN were effectively blocked by coadministration of tamoxifen, suggesting an ER-mediated effect.
ER␤'s role in synaptic plasticity and learning is also being investigated (71) . Male and female wild-type and ␤ERKO WYE mice were trained to associate a shock with a particular context (operant chamber) and cue (tone). Later, mice were tested to assess the memory strength for the context-shock relationship by placing them in the same chamber, but without sounding the cue. In this situation, wild-type mice freeze because they recognize the surroundings and associate them with the electric shock. Both male and female ␤ERKO WYE mice were significantly impaired in their freezing response to the context-indicative of failed associative learning of the shock with the context. It is thought that that memory encoding and retrieval of a context is dependent on the hippocampus. It is well established that genetic manipulations that disrupt hippocampal memory also disrupt forms of hippocampal synaptic plasticity, such as long-term potentiation. Interestingly, hippocampal slices taken from female ␤ERKO WYE exhibit a robust long-term potentiation deficit in area CA1 compared with wild-type mice. Specifically, fast synaptic transmission was impaired and long-term potentiation responses were blunted, and both of these deficits would be expected to impact learning and memory.
Models of Inflammatory Bowel Disease and Arthritis
Nonselective estrogens are known to have antiinflammatory properties and to interfere with NFB activity (72, 73) and thus it was possible that ER␤ might be capable of mediating this activity. Many models of inflammation exist, but the first model we used was the HLA-B27 transgenic rat. These rats develop inflammation in the intestine, joint, and skin and are used as models of inflammatory bowel disease and rheumatoid arthritis (74) . When administered to fully diseased rats, ERB-041 and WAY-202196 reversed the animals' symptoms of chronic diarrhea and reduced intestinal inflammation (25, 41 ERB-041 and WAY-202196 were also tested in the Lewis rat adjuvant-induced arthritis model, a well-established model of rheumatoid arthritis. Both these compounds reduced clinical signs of arthritis to near normal levels and significantly improved joint histology scores. In addition, ERB-041 reversed the majority of gene expression changes caused by disease induction in the liver, lymph node, and spleen and, as well, reversed many of the disease-induced plasma proteome changes (75) .
Although nonselective estrogens/selective ER modulators are active in both these models (76, 77) , ER␣-selective compounds have not been tested. Moreover, these observations cannot be confirmed using ERKO mice because they rely on specific genetic models of disease. Our experience with Wyeth ER␤-selective agonists is that they are not general antiinflammatory agents because they are inactive in many other models of inflammation, including collagen-induced arthritis, dextran sulfate sodium-induced colitis, carrageeninduced paw edema, lipopolysaccharide-induced haptoglobin production, experimental allergic encephalitis, and passive cutaneous anaphalaxis (Ref. 78 and Harris, H.A., unpublished observations). Finally it should be mentioned that a clear role for ER␣-dependent antiinflammatory activity has been established in some in vivo models; thus, antiinflammatory activity is not a unique property to ER␤ (78) (79) (80) (81) .
Endometriosis
Endometriosis is an estrogen-dependent disease with a significant inflammatory component (82) . Although it may seem counterintuitive to evaluate an ER agonist in models of this disease, given the antiinflammatory activity seen in other models, it seemed a reasonable idea to pursue. Although this disease occurs naturally only in primates, several rodent models exist, and one well-accepted model uses human endometrial tissue implanted as xenografts into nude mice (83, 84) . ERB-041 was tested in both ovariectomized and gonad intact mice with established endometriosis lesions, and after 2 wk of treatment, 40-75% of the mice were completely lesion free (85) . Only ER␣ was detected in recovered lesions (regardless of treatment), and thus it is speculated that ERB-041 may be stimulating the macrophages and/or natural killer cells of the nude mice to recognize the exogenous endometrial tissue as foreign and clear it. Clearly the in vivo profile of a selective ER␤ agonist is not only a subset of estradiol's activity.
Trauma and Sepsis Models
It has become apparent in recent years that females have a lower susceptibility for, and an improved survival from, traumatic injury and sepsis (86) . There is a large body of work showing androgen's deleterious effects and estrogen's protective qualities. Recent work is beginning to delineate the contributions of ER␣ and ER␤ to this beneficial effect. For the sake of brevity, only data relating to ER␤ will be presented here. In a rat model of trauma-hemorrhage, which examines lung injury, estradiol and DPN were equally effective in reducing a variety of inflammatory mediators including inducible nitric oxide synthase and IL-6, as well as markers of tissue damage such as lactate dehydroge-nase and total protein content of the bronchioalveolar fluid. PPT was ineffective on these parameters (87) . In a similar study, designed to examine cardiac function, DPN, but not PPT, improved cardiac output and stroke volume. In addition DPN, but not PPT, maintained heat shock proteins 32, 60, 70, and 90 (88) .
WAY-202196 has been examined in three models of systemic infection, the second and third of which are used as models of sepsis: 1) mouse listeriosis, 2) Pseudomonas infection in the neutropenic rat, and 3) mouse cecal ligation and puncture (89) . Whereas a single oral dose of WAY-202196 did not positively or negatively affect response to Listeria infection, a monoclonal antibody to TNF␣ increased susceptibility to infection (lowered the LD 50 ). Thus, WAY-202196 was not globally immunosuppressive in this model.
The Pseudomonas infection model aims to replicate the human situation of an immunocompromised patient (e.g. cancer patient receiving radio-or chemotherapy) who develops an infection. In this model, multiple doses of WAY-202196 increased survival (25-83%) and improved intestinal histology. The mouse cecal ligation and puncture model induces acute bacterial peritonitis (for review, see Ref. 90 ). When WAY-202196 was tested in this model, it improved survival (0% vs. 83%) and also reduced intestinal injury.
Leukemia
At 18 months of age, ␤ERKO KI mice of both sexes have grossly enlarged spleens compared with their wild-type counterparts, and is thought to be a consequence of bone marrow hypercellularity (91) . Moreover, these mice develop neoplasia resembling human chronic myeloid leukemia. To date, this phenotype has not been reported in other strains of ␤ERKO mice.
UNANSWERED QUESTIONS ABOUT ER␤ Is There a Unifying Mechanism of Action for ER␤-Mediated Activities?
As outlined above, ER␤ potentially affects many organ systems, and selective compounds have the potential to treat several disparate diseases. The field is currently sorely lacking in mechanistic hypotheses to explain how ER␤ might exert these effects. Although this dearth is understandable, not only because ER␤ was recently discovered, and within precedent, because we have no true mechanistic understanding of how estrogens work via ER␣ to ameliorate hot flushes and bone loss (despite having known about these activities for decades), mechanistic uncertainty undoubtedly handicaps further research. It seems doubtful that it will be possible to explain the diverse effects of this transcription factor with a single mechanism. Having said that, however, one system that bears further investigation is the hypothalamic-pituitary-adrenal (HPA) axis. Modulation of this axis may explain effects in certain inflammatory and behavioral models.
First, looking at expression in relevant brain regions, ER␤ is the predominant ER expressed in the rat paraventricular nucleus (10) , which is a key mediator of the stress response. Additionally, there is evidence for an interplay between corticosterone, estradiol, and ER␤ expression in the paraventricular nucleus (92) . Finally, ER␤ is colocalized with a subset of CRH neurons in the rat paraventricular nucleus and in vitro, ER␤ can upregulate the CRH promoter in response to estradiol (93) .
Several studies demonstrate an effect of nonselective estrogens on the HPA. It should be noted that effectiveness on these endpoints is highly dependent on dose and regimen. For the sake of brevity, only a few studies will be mentioned here. A single episode of restraint stress markedly elevated ACTH and corticosterone levels in rats, but chronic treatment with estradiol benzoate significantly reduced the ACTH response (with no effect on corticosterone levels) (94) . Interestingly, in this study, estradiol benzoate increased levels of other stress-responsive markers (adrenal tyrosine hydroxylase and dopamine ␤-hydroxylase mRNA) in unstressed animals, pointing out the system's complexity. In another stress-dependent model, estradiol reduced stress-induced expression of c-Fos in the paraventricular nucleus, although (as above) corticosterone levels were unaffected (95) .
Other studies have measured behavioral consequences of HPA modulation. In a study discussed above, Lund et al. (70) showed that all rats tested in the elevated plus maze had increased levels of corticosterone, but the levels seen in the DPN-treated animals were significantly lower than those treated with estradiol or PPT (which were significantly higher than vehicle-treated rats in contrast to the findings of Ref. 96) . Because both estradiol and DPN were effective at reducing anxiety in this model, the effects would seem not explainable by modulation of corticosterone levels, although it should be noted that it was only measured at one time point (30 min after returning to home cage).
In a similar study again using the open field and elevated plus maze tests, Walf and Frye (96) found that estradiol's effects in reducing anxiety were blunted by pretest restraint stress. Doses of estradiol that were effective in reducing stress also reduced corticosterone levels and these effects were also seen in unstressed untested rats. Estradiol's antianxiety action was likely not entirely via modulation of corticosterone levels, because although estradiol was ineffective in adrenalectomized rats, this was reversed by administration of low doses (but not high doses) of corticosterone.
Lewis rats, which are used for the adjuvant-induced arthritis model, have well-known defects in their HPA axis that render them hypersensitive to inflammatory stimuli (97) . Lipopolysaccharide stimulation of Fischer 344 rats (the control strain for Lewis rats) leads to robust up-regulation of CRH mRNA in the paraven-tricular nucleus and a modest down-regulation of ER␣ and ER␤ mRNA (97) . Neither of these responses is seen in Lewis rats, again suggesting interplay between ERs and the HPA.
Are There Expected Clinical Liabilities with Selective ER␤ Agonists?
Based on the biological profile of selective ER␤ agonists to date, are there any obvious clinical liabilities that might hinder their development? Answering this question, again, requires rigorous testing of a variety of compounds to separate observations based on mechanism from those that might be idiosyncratic. Given the widespread expression of ER␤, it was surprising to us that we could find essentially no ER␤-dependent genes in normal (healthy) mice dosed with estradiol (98) . This observation contributed to the construction of the challenge hypothesis, i.e. that ER␤'s function becomes apparent only when the animal is stressed, ill, or otherwise compromised. If this is true, then effects of ER␤ activation in normal tissues may not lead to many responses and will afford less opportunity for unwanted side effects.
One very difficult but critical question to answer is the influence of ER␤ agonists on the risk of developing breast cancer in humans. Preclinically, proliferative effects of estrogens on human breast cancer cells in vitro or in animal models of breast cancer is easily demonstrated. For example, a number of human breast cancer cell lines proliferate in response to estrogens, and antiestrogens or selective ER modulators, which are clinically useful agents to treat human cancers, block this effect. In addition, transgenic mice expressing the ER coactivator amplified in breast cancer 1/steroid receptor coactivator 3 develop mammary tumors whereas null mice are resistant (99, 100) . These studies have primarily focused on the role of ER␣ in mediating the effects of estrogens.
It should be remembered however, that, even though many estrogen-responsive preclinical models of breast cancer exist, a large-scale clinical trial involving more than 10,000 women taking 0.625 mg/d of conjugated equine estrogens for a mean of 6.8 yr demonstrated that this regimen did not increase the risk for developing breast cancer (101) . In fact, there was a trend toward a decreased risk (hazard ratio with 95% confidence interval ϭ 0.59-1.01). This observation demonstrates that the effects of estrogens seen in preclinical models of breast cancer do not wholly translate to humans.
ER␤ is expressed in the human mammary gland, and many studies have tried to define its role. The goal of mapping studies is to correlate expression of ER␣ and ER␤ with clinical parameters. It should be cautioned, however, that a correlation between two observations does not guarantee that they are causally related. Many such studies have been conducted, and the results from those published from 1997-2003 (mRNA) or 1999-2003 (protein) are summarized in a recent review (102) , and the conclusions are concordant with work published more recently (103) (104) (105) (106) (107) (108) (109) . Regarding mRNA expression, the majority of these studies indicate that healthy mammary glands express more ER␤ mRNA than do breast cancer samples. ER␤ expression has been correlated with tamoxifen sensitivity and disease-free/overall survival. In breast cancer samples, ER␣ is usually the predominant ER, and ER␤ expression has been reported to decrease during carcinogenesis. Promoter methylation has been implicated as a cause of reduced ER␤ expression (110) , and a decrease in ER␤ expression has also been reported for other cancers such as prostate, endometrium, ovary, and colon and has led to the hypothesis that ER␤ is a potential tumor suppressor (see Ref. 111 for review).
A number of in vitro functional studies have been performed to examine the effect of ER␤ expression on the proliferation of breast cancer cells (112) (113) (114) (115) (116) . Although the results are not unanimous, the majority of studies conclude that an increase in ER␤ expression decreases cell proliferation. Additionally, when ligand dependence of the effects was evaluated, most studies agree that the effects seen are ligand independent. Therefore, they may have minimal implication for predicting the activity of an ER␤-selective agonist. Taken together, the current data do not support a role for ER␤'s ligand-dependent activity in the genesis or progression of breast cancer.
CONCLUDING REMARKS
The story of ER␤ is a tribute to the power and possibility of genomics as a means to identify new protein family members of high scientific interest and possible clinical utility. However, although identification is relatively straightforward given today's research and bioinformatics tools, defining function of a new protein can be seemingly slow and challenging even in a field where so much is known about its close relatives. It has taken almost 9 yr to make significant progress toward understanding the in vivo activities of ER␤, and at that, we have poor understanding of the mechanisms that underlie the in vivo observations described in this review. Additionally, the degree to which ER␤ contributes to normal estrogen action has yet to be determined. The time needed to make these discoveries is really a reflection of the enormity and complexity of the task and the necessity of many disciplines to work together. The field of ER␤ research has been a remarkable partnership between public and private sector research efforts and as well between chemists, structural biologists, physiologists, and pharmacologists. With the research tools we now have available and results from ongoing clinical trials, the next few years should yield even more exciting findings and significant progress in our understanding of ER␤'s function and therapeutic utility.
Note Added in Proof
Since this manuscript was accepted, data using PPT, ERB-041 and WAY-202196 have been published showing that ER␣ stimulation, in combination with progesterone, is necessary and sufficient to elicit changes on mouse mammary gland morphology and regulation of at least one mRNA marker of hormone response (117) . 
